Dermata Therapeutics, Inc. (DRMA)
| Market Cap | 5.23M +5.2% |
| Revenue (ttm) | n/a |
| Net Income | -7.10M |
| EPS | -4.03 |
| Shares Out | 4.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 56,170 |
| Open | 1.350 |
| Previous Close | 1.350 |
| Day's Range | 1.280 - 1.350 |
| 52-Week Range | 1.100 - 8.000 |
| Beta | 0.67 |
| Analysts | Buy |
| Price Target | 4.00 (+207.69%) |
| Earnings Date | May 13, 2026 |
About DRMA
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for DRMA stock is "Buy" and the 12-month stock price target is $4.0.
News
Dermata Therapeutics Registration statement: Registration filing
Dermata Therapeutics filed a registration statement on May 22, 2026, providing details about a securities offering with the SEC.
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
- Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products - - Dermata plans to launch its first DTC product, the Tome Foundational Treatment, a once-weekly mask to...
Dermata Therapeutics Quarterly report: Q1 2026
Dermata Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Dermata Therapeutics Earnings release: Q1 2026
Dermata Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Dermata Therapeutics Proxy statement: Proxy filing
Dermata Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Dermata Therapeutics Proxy statement: Proxy filing
Dermata Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Dermata Therapeutics Proxy statement: Proxy filing
Dermata Therapeutics filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
Dermata receives notice of acceptance of Australian patent application
Dermata Therapeutics (DRMA) announced the Australian Patent Office has accepted its patent application for its topical dermal filler program utilizing its BDS. The patent, entitled “Compositions for t...
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers - - The Company also has allowed and issued patents in the US, Australi...
Dermata Therapeutics price target lowered to $4 from $10 at Maxim
Maxim lowered the firm’s price target on Dermata Therapeutics (DRMA) to $4 from $10 and keeps a Buy rating on the shares. The company’s Q4 results saw operating expenses slightly…
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
- Dermata announced a strategic pivot to develop and commercialize direct-to-consumer ("DTC") skincare products under the brand name Tome - - Dermata plans to launch its first DTC product, our Foundat...
Dermata Therapeutics Annual report: Q4 2025
Dermata Therapeutics has published its Q4 2025 annual report on March 26, 2026.
Dermata Therapeutics Earnings release: Q4 2025
Dermata Therapeutics released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
Dermata Therapeutics appoints Kyra Peckaitis as VP, marketing
Dermata Therapeutics (DRMA) announced the appointment of Kyra Peckaitis as Vice President, Marketing. Ms. Peckaitis is a multi-disciplinary brand marketer and will lead Dermata’s new brand launch, Tom...
Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
- Kyra Peckaitis will lead the launch of Dermata's recently announced Tome skincare brand - SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") ...
Dermata Therapeutics announces release of Tome Skincare
Dermata Therapeutics (DRMA) announces the branding of its latest innovation in skincare: Tome, which aims to introduce “skintech at home”. The Company’s Tome skincare line will bring intentionally dev...
Dermata Opens a New Chapter with the Release of Tome Skincare
-The oldest new thing in skincare - - Dermata expects to launch its first product in the middle of 2026 - SAN DIEGO, CA / ACCESS Newswire / March 5, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nas...
Dermata Therapeutics files to sell 1.48M shares of common stock for holders
17:03 EST Dermata Therapeutics (DRMA) files to sell 1.48M shares of common stock for holders
Dermata Therapeutics Registration statement: Registration filing
Dermata Therapeutics filed a registration statement on January 22, 2026, providing details about a securities offering with the SEC.
Dermata Therapeutics receives notice of grant of patent for acne treatment
Dermata Therapeutics (DRMA) announced the Australian Patent Office has granted its patent application for its Spongilla technology combination as a method for treating acne. The patent, entitled “Comp...
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
This patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combination as a method to topically treat acne Dermata expects to launch a new once-weekly, over-the-coun...
Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / December 29, 2025 / Dermata Th...
Dermata Therapeutics prices 2.02M shares at $2.04 in private placement
Dermata Therapeutics (DRMA) entered into definitive agreements for the issuance and sale of an aggregate of 2,022,062 shares of common stock, series C warrants to purchase up to 2,022,062 shares…
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / December 24, 2025 / Dermata Th...
Dermata Therapeutics to reveal brand name for OTC skincare business
Dermata Therapeutics (DRMA) will soon reveal its new brand name for its over-the-counter skincare business representing its evolution toward a more direct, science-first era of dermatologic innovation...